---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-24-000877"
form_type: "8-K"
ticker: "LNAI"
cik: "0001527728"
company_name: "Lunai Bioworks Inc."
filed_at: "2024-05-24T23:59:59+00:00"
generated_at: "2026-06-01T08:41:41.251971+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Renovaro signs MoU with Amsterdam UMC to form joint cancer immunotherapy company

## Summary
- Signed MoU to establish Newco in Netherlands for personalized cancer immunotherapy.
- Combines Renovaro's proprietary dendritic vaccine tech with Amsterdam UMC's immunomodulatory expertise.
- Newco to be headquartered in Amsterdam; clinical activities may move there.
- Final commitments subject to due diligence and approval from both executive boards.
- No financial terms or deal value disclosed in the press release.

## SEC filing metadata
- accession: 0001731122-24-000877
- form_type: 8-K
- ticker: LNAI
- cik: 0001527728
- company_name: Lunai Bioworks Inc.
- filed_at: 2024-05-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527728/000173112224000877/0001731122-24-000877-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527728/000173112224000877/e5707_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-24-000877
- JSON: https://secwatch.observer/filing/0001731122-24-000877.json
- Plain text: https://secwatch.observer/filing/0001731122-24-000877.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.